Diferencia entre revisiones de «Hydromorphone»
(Text replacement - "4 mg" to "4mg") |
(Add See Also and References) |
||
| (No se muestran 7 ediciones intermedias de 4 usuarios) | |||
| Línea 7: | Línea 7: | ||
===Severe Pain=== | ===Severe Pain=== | ||
*Oral: 2-4mg PO q4-6h PRN | *Oral: 2-4mg PO q4-6h PRN | ||
*IV: 0.2- | *IV: 0.2-1mg IV q2-3h PRN | ||
*IM: 1-2mg IM q2-3h PRN (not recommended secondary to variable absorption) | *IM: 1-2mg IM q2-3h PRN (not recommended secondary to variable absorption) | ||
| Línea 28: | Línea 28: | ||
*Allergy to class/drug | *Allergy to class/drug | ||
*Respiratory depression | *Respiratory depression | ||
* [[CNS depression]] | |||
* MAO inhibitor use in prior 2 weeks | |||
* GI obstruction or ileus | |||
==Adverse Reactions== | ==Adverse Reactions== | ||
| Línea 34: | Línea 37: | ||
*Apnea | *Apnea | ||
*Hypotension | *Hypotension | ||
* | *Syncope | ||
* | *Bradycardia | ||
* | *Urinary retention | ||
*Seizures | *Seizures | ||
* | *[[Anaphylaxis]] | ||
===Common=== | ===Common=== | ||
| Línea 55: | Línea 58: | ||
*Excretion: urine | *Excretion: urine | ||
*Mechanism of Action:binds to various opioid receptors | *Mechanism of Action:binds to various opioid receptors | ||
==See Also== | |||
*[[Opioids]] | |||
*[[Acute pain management]] | |||
*[[Opioid overdose]] | |||
==References== | |||
<references/> | |||
[[Category:Pharmacology]] | [[Category:Pharmacology]] | ||
==Indications by Condition== | |||
''The following table is automatically generated from disease/condition pages across WikEM.'' | |||
{{#ask:[[Has DrugName::Hydromorphone]] | |||
|?Has Indication=Indication | |||
|?Has Dose=Dose | |||
|?Has Context=Context | |||
|?Has Route=Route | |||
|?Has Population=Population | |||
|format=table | |||
|headers=plain | |||
|mainlabel=- | |||
|sort=Has Indication | |||
|limit=50 | |||
}} | |||
Revisión actual - 09:11 22 mar 2026
General
- Type: Opioids
- Dosage Forms: PO, SC, IM, IV, PR, PCA
- Common Trade Names: Dilaudid, Exalgo
Adult Dosing
Severe Pain
- Oral: 2-4mg PO q4-6h PRN
- IV: 0.2-1mg IV q2-3h PRN
- IM: 1-2mg IM q2-3h PRN (not recommended secondary to variable absorption)
Pediatric Dosing
Severe Pain
- > 6 months, > 50 kg: 0.5 - 2mg PO/SC/IM/IV q3-6h.
- Alternatively: 15-20 mcg/kg q3-6h.
Special Populations
- Pregnancy Rating: C
- Lactation Risk Categories: probably safe
- Renal Dosing
- Adult: mod-severe impairment: decrease start dose, amount not defined
- Pediatric: mod-severe impairment: decrease start dose, amount not defined
- Hepatic Dosing
- Adult: Child-pugh class B: decrease start dose 50-75%
- Pediatric: Child-pugh class B:decrease start dose 50-75%
Contraindications
- Allergy to class/drug
- Respiratory depression
- CNS depression
- MAO inhibitor use in prior 2 weeks
- GI obstruction or ileus
Adverse Reactions
Serious
- Respiratory Depression
- Apnea
- Hypotension
- Syncope
- Bradycardia
- Urinary retention
- Seizures
- Anaphylaxis
Common
- Nausea
- Rash
- Headache
- Fatigue
- xerostomia
- constipation
- Tremor
- urinary retention
Pharmacology
- Half-life: 2.3 hour
- Metabolism: Liver
- Excretion: urine
- Mechanism of Action:binds to various opioid receptors
See Also
References
Indications by Condition
The following table is automatically generated from disease/condition pages across WikEM.
| Indication | Dose | Context | Route | Population |
|---|---|---|---|---|
| Acute pain management | 0.015 mg/kg IV or 1-2 mg IM; titrate 0.5-1.0 mg IV increments | Step 3 - Severe pain (opioid) | IV/IM | Adult |